Parabilis Medicines

Parabilis Medicines is a clinical-stage biopharmaceutical company focused on developing transformative medicines for historically "undruggable" protein targets that drive human diseases, particularly in oncology. The company, formerly known as FogPharma, was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States. Parabilis Medicines leverages its proprietary Helicon™ platform to pioneer a novel therapeutic modality: stabilized helical peptides engineered to bind and precisely modulate proteins that have been beyond the reach of conventional medicines like small molecules or biologics. These Helicons are designed to have the target-surface coverage of an antibody and the cell permeability of a small molecule, enabling them to enter cells and block flat disease targets. The company's lead product candidate, zolucatetide (also known as FOG-001), is an investigational therapy that inhibits the β-catenin:TCF interaction, a critical downstream node of the Wnt/β-catenin pathway implicated in various solid tumors. Zolucatetide is currently being evaluated in clinical trials across multiple solid tumor indications, including desmoid tumors and familial adenomatous polyposis, with over 150 patients dosed to date. Parabilis Medicines plans to initiate a Phase 3 registrational trial for zolucatetide in desmoid tumors in the first half of 2027. The company also has preclinical programs, including investigational degraders of ERG and ARON for prostate cancer. Parabilis Medicines has not generated product revenue to date and reported a net loss of approximately $153 million for the 12 months ended March 31, 2026. The company is expected to list on NASDAQ under the ticker symbol PBLS on June 10, 2026. Sources: [1] https://parabilismed.com/company/who-we-are/ [2] https://stockanalysis.com/stocks/pbls/company/ [3] https://tickerspark.ai/market/parabilis-medicines-ipo [4] https://parabilismed.com/company/how-we-got-here/ [5] https://www.thepharmaletter.com/ones-to-watch/parabilis-medicines [6] https://parabilismed.com/press-release/parabilis-medicines-receives-fda-fast-track-designation-for-fog-001-the-first-and-only-direct-inhibitor-of-the-%CE%B2-catenintcf-interaction-for-the-treatment-of-desmoid-tumors/ [7] https://www.ipox.com/ipo-calendar/parabilis-medicines [8] https://www.renaissancecapital.com/IPO-Center/News/119549/Cancer-biotech-Parabilis-Medicines-sets-terms-for-$450-million-IPO [9] https://www.investing.com/equities/parabilis-medicines-inc